Here, E2 was used to initially validate that ERα could be a potential therapeutic target for DMD and to confirm that activation of ERα promoted skeletal muscle regeneration and improved the therapeutic value of ERα/ERRα agonist for DMD needed to be emphasized. Here, ESRRA is linked to Duchenne muscular dystrophy.